1. Home
  2. SPTN vs OMER Comparison

SPTN vs OMER Comparison

Compare SPTN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPTN
  • OMER
  • Stock Information
  • Founded
  • SPTN 1917
  • OMER 1994
  • Country
  • SPTN United States
  • OMER United States
  • Employees
  • SPTN N/A
  • OMER N/A
  • Industry
  • SPTN Food Distributors
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPTN Consumer Discretionary
  • OMER Health Care
  • Exchange
  • SPTN Nasdaq
  • OMER Nasdaq
  • Market Cap
  • SPTN 596.4M
  • OMER 188.1M
  • IPO Year
  • SPTN N/A
  • OMER 2009
  • Fundamental
  • Price
  • SPTN $26.53
  • OMER $2.97
  • Analyst Decision
  • SPTN Hold
  • OMER Strong Buy
  • Analyst Count
  • SPTN 1
  • OMER 5
  • Target Price
  • SPTN $26.90
  • OMER $18.00
  • AVG Volume (30 Days)
  • SPTN 1.2M
  • OMER 901.8K
  • Earning Date
  • SPTN 08-14-2025
  • OMER 08-06-2025
  • Dividend Yield
  • SPTN 3.29%
  • OMER N/A
  • EPS Growth
  • SPTN N/A
  • OMER N/A
  • EPS
  • SPTN N/A
  • OMER N/A
  • Revenue
  • SPTN $9,652,685,000.00
  • OMER N/A
  • Revenue This Year
  • SPTN $6.00
  • OMER N/A
  • Revenue Next Year
  • SPTN N/A
  • OMER $468.75
  • P/E Ratio
  • SPTN N/A
  • OMER N/A
  • Revenue Growth
  • SPTN 0.26
  • OMER N/A
  • 52 Week Low
  • SPTN $17.30
  • OMER $2.95
  • 52 Week High
  • SPTN $26.65
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • SPTN 77.75
  • OMER 33.78
  • Support Level
  • SPTN $26.37
  • OMER $3.11
  • Resistance Level
  • SPTN $26.56
  • OMER $3.60
  • Average True Range (ATR)
  • SPTN 0.36
  • OMER 0.24
  • MACD
  • SPTN 0.83
  • OMER 0.05
  • Stochastic Oscillator
  • SPTN 98.13
  • OMER 2.86

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: